Fig. 3.

Association of FAT1 signature with radiotherapy in HNSCC patients. (A, B) Five‐year OS rates of FAT1‐LR and FAT1‐HR subgroups in HNSCC patients who did/did not receive radiotherapy (n = 391 and 223, respectively) were depicted using Kaplan–Meier plots. (C, D) In the same way, five‐year OS rates of patients were depicted according to radiotherapy in the FAT1‐LR (n = 203) and FAT1‐HR subgroups (n = 411). Patients in the FAT1‐LR subgroup benefited significantly from radiotherapy (p = 3e−04, 4e−04, respectively; A, C). Log‐rank test was used to estimate the P value. *P < 0.05. HNSCC, head and neck squamous cell carcinoma; FAT1‐HR, FAT1‐associated high risk; FAT1‐LR, FAT1‐associated low risk; OS, overall survival; RFS, recurrence‐free survival.